To shorten this interval even more, the authors developed a new emergency treatment protocol for managing ruptured aneurysms within a few hours after a patient presents with aneurysmal SAH. To test the effectiveness of the new process, the authors compared the scientific courses of 442 patients treated in this manner between 2008 and 2011 with the clinical courses of 423 individuals treated between 2001 and 2004 under a different protocol where early treatment was defined as fewer than 3 days after the initial SAH.In this research of letermovir, the incidence of neutropenia was nearly similar in the letermovir and placebo groups . These findings comparison with reported incidences of neutropenia as high as 58 percent with valganciclovir or more to 26 percent with CMX001.14-17 However, our study included a relatively small number of patients and did not allow for comparisons of long-term survival outcomes. In conclusion, this small 12-week trial showed that prophylactic therapy with letermovir in recipients of allogeneic hematopoietic-cell transplants was efficacious and as secure as placebo, without apparent safety concerns, including hematologic and renal toxicity. These total results are consistent with those of a previous phase 2, proof-of-concept trial involving a small amount of recipients of solid-organ transplants.18..